Form 4: Beam Therapeutics CLO Sells Shares Under 10b5-1 Plan

Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold 1,371 shares of common stock for $34 per share under a pre-arranged trading plan.

Summary

• Christine Bellon, Chief Legal Officer of Beam Therapeutics Inc. (BEAM), reported a sale of common stock.
• The transaction involved the disposition of 1,371 shares of common stock.
• The shares were sold at a price of $34 per share.
• The transaction date was January 22, 2026.
• Following this transaction, Christine Bellon beneficially owns 95,667 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person on September 16, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a pre-planned sale under a Rule 10b5-1 trading plan, which is typically for personal financial management and not indicative of a change in company outlook.

Negatives

• Reduction in direct insider ownership by Christine Bellon, Chief Legal Officer, through the sale of 1,371 shares.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, which is generally not considered a significant signal given the pre-arranged nature of the sale.

Key Dates

Recommendation

The sale of 1,371 shares by the Chief Legal Officer, Christine Bellon, was conducted under a pre-arranged Rule 10b5-1 trading plan. Such plans are typically established for personal financial planning purposes (e.g., diversification, liquidity) and are not usually indicative of management's view on the company's immediate future prospects. The transaction size is relatively small in the context of a publicly traded company. Therefore, this specific insider sale alone does not warrant a change in investment recommendation, and a 'hold' stance is maintained, pending further fundamental analysis of the company's operations and financial performance.

Keywords

Beam Therapeutics, BEAM, Insider Trading, Form 4, Christine Bellon, Stock Sale, 10b5-1 Plan, Chief Legal Officer